Annual FCF
-$239.25 M
-$13.54 M-6.00%
31 December 2023
Summary:
Allogene Therapeutics annual free cash flow is currently -$239.25 million, with the most recent change of -$13.54 million (-6.00%) on 31 December 2023. During the last 3 years, it has fallen by -$58.20 million (-32.14%). ALLO annual FCF is now -399.61% below its all-time high of -$47.89 million, reached on 31 December 2018.ALLO Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$44.54 M
+$19.04 M+29.95%
30 September 2024
Summary:
Allogene Therapeutics quarterly free cash flow is currently -$44.54 million, with the most recent change of +$19.04 million (+29.95%) on 30 September 2024. Over the past year, it has increased by +$11.00 million (+19.80%). ALLO quarterly FCF is now -890980.00% below its all-time high of $5000.00, reached on 31 March 2018.ALLO Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$217.93 M
+$11.00 M+4.80%
30 September 2024
Summary:
Allogene Therapeutics TTM free cash flow is currently -$217.93 million, with the most recent change of +$11.00 million (+4.80%) on 30 September 2024. Over the past year, it has increased by +$31.22 million (+12.53%). ALLO TTM FCF is now -4358640.00% below its all-time high of $5000.00, reached on 31 March 2018.ALLO TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ALLO Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -6.0% | +19.8% | +12.5% |
| 3 y3 years | -32.1% | +14.7% | -16.3% |
| 5 y5 years | -399.6% | +11.5% | -48.7% |
ALLO Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -32.1% | at low | -1.5% | +36.5% | -16.3% | +12.5% |
| 5 y | 5 years | -399.6% | at low | -62.7% | +36.5% | -48.7% | +12.5% |
| alltime | all time | -399.6% | at low | <-9999.0% | +36.5% | <-9999.0% | +12.5% |
Allogene Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$44.54 M(-29.9%) | -$217.93 M(-4.8%) |
| June 2024 | - | -$63.59 M(+13.7%) | -$228.93 M(+0.6%) |
| Mar 2024 | - | -$55.91 M(+3.7%) | -$227.48 M(-4.9%) |
| Dec 2023 | -$239.25 M(+6.0%) | -$53.89 M(-3.0%) | -$239.25 M(-4.0%) |
| Sept 2023 | - | -$55.54 M(-10.6%) | -$249.15 M(+3.2%) |
| June 2023 | - | -$62.15 M(-8.2%) | -$241.49 M(+8.2%) |
| Mar 2023 | - | -$67.67 M(+6.1%) | -$223.25 M(-1.1%) |
| Dec 2022 | -$225.71 M(+9.4%) | -$63.79 M(+33.2%) | -$225.71 M(+8.5%) |
| Sept 2022 | - | -$47.88 M(+9.0%) | -$208.09 M(-2.0%) |
| June 2022 | - | -$43.91 M(-37.4%) | -$212.44 M(-3.7%) |
| Mar 2022 | - | -$70.14 M(+51.9%) | -$220.61 M(+7.0%) |
| Dec 2021 | -$206.26 M | -$46.17 M(-11.6%) | -$206.26 M(+10.0%) |
| Sept 2021 | - | -$52.23 M(+0.3%) | -$187.47 M(-2.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2021 | - | -$52.07 M(-6.7%) | -$193.07 M(+5.1%) |
| Mar 2021 | - | -$55.79 M(+103.8%) | -$183.78 M(+1.5%) |
| Dec 2020 | -$181.05 M(-3.8%) | -$27.38 M(-52.7%) | -$181.05 M(-17.0%) |
| Sept 2020 | - | -$57.84 M(+35.2%) | -$218.05 M(+3.6%) |
| June 2020 | - | -$42.77 M(-19.4%) | -$210.55 M(+5.0%) |
| Mar 2020 | - | -$53.06 M(-17.6%) | -$200.52 M(+6.6%) |
| Dec 2019 | -$188.14 M(+292.9%) | -$64.38 M(+27.9%) | -$188.14 M(+28.4%) |
| Sept 2019 | - | -$50.34 M(+53.7%) | -$146.56 M(+27.7%) |
| June 2019 | - | -$32.75 M(-19.5%) | -$114.74 M(+29.5%) |
| Mar 2019 | - | -$40.68 M(+78.4%) | -$88.57 M(+85.0%) |
| Dec 2018 | -$47.89 M | -$22.80 M(+23.2%) | -$47.89 M(+90.9%) |
| Sept 2018 | - | -$18.51 M(+181.1%) | -$25.09 M(+281.3%) |
| June 2018 | - | -$6.58 M(<-9900.0%) | -$6.58 M(<-9900.0%) |
| Mar 2018 | - | $5000.00 | $5000.00 |
FAQ
- What is Allogene Therapeutics annual free cash flow?
- What is the all time high annual FCF for Allogene Therapeutics?
- What is Allogene Therapeutics annual FCF year-on-year change?
- What is Allogene Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Allogene Therapeutics?
- What is Allogene Therapeutics quarterly FCF year-on-year change?
- What is Allogene Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Allogene Therapeutics?
- What is Allogene Therapeutics TTM FCF year-on-year change?
What is Allogene Therapeutics annual free cash flow?
The current annual FCF of ALLO is -$239.25 M
What is the all time high annual FCF for Allogene Therapeutics?
Allogene Therapeutics all-time high annual free cash flow is -$47.89 M
What is Allogene Therapeutics annual FCF year-on-year change?
Over the past year, ALLO annual free cash flow has changed by -$13.54 M (-6.00%)
What is Allogene Therapeutics quarterly free cash flow?
The current quarterly FCF of ALLO is -$44.54 M
What is the all time high quarterly FCF for Allogene Therapeutics?
Allogene Therapeutics all-time high quarterly free cash flow is $5000.00
What is Allogene Therapeutics quarterly FCF year-on-year change?
Over the past year, ALLO quarterly free cash flow has changed by +$11.00 M (+19.80%)
What is Allogene Therapeutics TTM free cash flow?
The current TTM FCF of ALLO is -$217.93 M
What is the all time high TTM FCF for Allogene Therapeutics?
Allogene Therapeutics all-time high TTM free cash flow is $5000.00
What is Allogene Therapeutics TTM FCF year-on-year change?
Over the past year, ALLO TTM free cash flow has changed by +$31.22 M (+12.53%)